LigaChem Biosciences Inc (141080)

Currency in KRW
137,900
-1,100(-0.79%)
Delayed Data·

141080 Financial Summary

Key Ratios

P/E Ratio203.32
Price/Book8.49
Debt / Equity0.41%
Return on Equity4.15%
Dividend Yield0.00%
EBITDA-15.90B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2014
31/12
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of KRW (except for per share items)

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 162,000
(+17.48% Upside)

Earnings

Latest Release
May 19, 2025
EPS / Forecast
729.64 / --
Revenue / Forecast
51.60B / 78.37B
EPS Revisions
Last 90 days

FAQ

What were LigaChem Biosciences's earnings for the latest quarter?

The LigaChem Biosciences EPS (TTM) is 683.16. LigaChem Biosciences reported sales of 51,575.56, net income of 26,472.89, and EPS of 729.64 for the latest quarter.

What was LigaChem Biosciences's net income for the latest quarter?

LigaChem Biosciences's net income for the latest quarter was 26,472.89.

How did LigaChem Biosciences's performance compare year-over-year in the latest quarter?

The company's revenue moved from 33,668.61 in the previous quarter to 51,575.56 in the latest quarter, and net income moved from -5,419.09 to 26,472.89 compared to the previous quarter.

What is LigaChem Biosciences's net profit margin on a TTM basis?

LigaChem Biosciences's trailing twelve months (TTM) net profit margin is 6.20%.

How does LigaChem Biosciences's debt to equity ratio compare to industry standards?

LigaChem Biosciences's total debt-to-equity ratio is 0.41%.

What is LigaChem Biosciences's return on investment on a TTM basis?

LigaChem Biosciences's trailing twelve months (TTM) return on investment (ROI) is 4.15%.

Did LigaChem Biosciences gain or lose cash last quarter?

In the latest quarter, LigaChem Biosciences's net change in cash was -20,551.82 million.

What were LigaChem Biosciences's total assets and liabilities in the latest quarter?

As of the latest quarter, LigaChem Biosciences reported total assets of 739,838.19 million and total liabilities of 101,342.12 million.

How has LigaChem Biosciences's total revenue grown this year?

LigaChem Biosciences's total revenue was 33,668.61 in the previous quarter and 51,575.56 in the latest quarter.

What is LigaChem Biosciences's gross margin on a TTM basis?

LigaChem Biosciences's trailing twelve months (TTM) gross margin is 88.97%.

What was LigaChem Biosciences's revenue per share for the latest quarter?

LigaChem Biosciences's revenue per share for the latest quarter was 1,021.26.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.